Literature DB >> 26474322

Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese.

Tania Cestari1, Clarissa Prati1, Doris B Menegon1, Zilda N Prado Oliveira2, Maria Cecília R Machado2, Juliana Dumet2, Juliana Nakano2, Dédée F Murrell3.   

Abstract

BACKGROUND: The Quality of Life Evaluation in Epidermolysis Bullosa (QoLEB) questionnaire was developed for use in English-speaking individuals.
OBJECTIVES: The aims of this study were to translate the QoLEB into Brazilian Portuguese, to culturally adapt it, and to verify its reliability and validity.
METHODS: The study followed the steps proposed by the World Health Organization, which include: translation; evaluation by a panel of experts and patients; back translation; and linguistic and cultural adaptation. All subjects were examined and assessed using the QoLEB and the Dermatology Life Quality Index (DLQI) or the Children's Dermatology Life Quality Index (CDLQI). Translation and cultural and linguistic adaptation were conducted by 10 patients, three translators, and the bilingual authors.
RESULTS: The population was composed of 40 children (mean age: 8,15 years) and 17 adults (mean age: 33 years). Among the children, eight had epidermolysis bullosa (EB) simplex (EBS), one had junctional EB (JEB), and 31 had dystrophic EB (DEB). In the adult group, four of the subjects had EBS, one had JEB, and 12 had DEB. Mean ± standard deviation (SD) scores on the QoLEB in children were 10.60 ± 7.13 in EBS subjects, 9.71 ± 7.87 in children with dominant DEB (DDEB), and 14.25 ± 9.67 in children with recessive DEB (RDEB). Mean ± SD scores in adults were 12.50 ± 9.95 in EBS subjects, 12.00 ± 5.83 in DDEB subjects, and 20.20 ± 9.21 in RDEB subjects. The QoLEB-BP (Brazilian Portuguese) showed high internal consistency (Cronbach's α = 0.88) and high test-retest reliability (intraclass correlation coefficient: 0.70), confirming the internal consistency and reproducibility of this Portuguese version. There were significant correlations between QoLEB scores and both CDLQI (Pearson's r = 0.688, P < 0.002) and DLQI (Pearson's r = 0.807, P < 0.001) scores.
CONCLUSIONS: Epidermolysis bullosa has marked impacts on the lives of EB patients and their families, which are strongly correlated with disease severity. The Brazilian Portuguese version of the QoLEB is validated and can be recommended for use in subsequent studies.
© 2015 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2015        PMID: 26474322     DOI: 10.1111/ijd.12819

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  10 in total

Review 1.  Psychosocial impact of inherited and autoimmune blistering diseases.

Authors:  Swaranjali V Jain; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2018-01-08

2.  The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language.

Authors:  Atoosa Yazdanshenas; Ezatollah Naderi; Hamideh Moravvej; Kazem Heidari; Masoomeh Faghankhani; Hassan Vahidnezhad; Nikoo Mozafari
Journal:  Int J Womens Dermatol       Date:  2020-06-03

3.  A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).

Authors:  Clare L Rogers; Matthew Gibson; Johannes S Kern; Linda K Martin; Susan J Robertson; Benjamin S Daniel; John C Su; Oliver G C Murrell; Grant Feng; Dedee F Murrell
Journal:  JAAD Int       Date:  2021-01-21

Review 4.  Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation.

Authors:  John W Frew; Mark Davidson; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2017-12-29       Impact factor: 4.123

5.  Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex.

Authors:  Jennifer Brun; Christine Chiaverini; Caroline Devos; Stéphanie Leclerc-Mercier; Juliette Mazereeuw; Emmanuelle Bourrat; Annabel Maruani; Stéphanie Mallet; Claire Abasq; Alice Phan; Pierre Vabres; Ludovic Martin; Christine Bodemer; Sylvie Lagrange; Jean-Philippe Lacour
Journal:  Orphanet J Rare Dis       Date:  2017-06-28       Impact factor: 4.123

Review 6.  A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.

Authors:  Jean Yuh Tang; M Peter Marinkovich; Eleanor Lucas; Emily Gorell; Albert Chiou; Ying Lu; Jodie Gillon; Dipen Patel; Dan Rudin
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

7.  Translation and validation of the Arabic version of the osteoarthritis quality of life questionnaire (OAQoL) in Saudi patients with osteoarthritis.

Authors:  Mansour AlAjmi; Sameer Al-Ghamdi
Journal:  Health Qual Life Outcomes       Date:  2021-03-17       Impact factor: 3.186

8.  Transcultural Validation of a Spanish Version of the Quality of Life in Epidermolysis Bullosa Questionnaire.

Authors:  Alvaro Rafael Villar Hernández; Fernando Molero Alonso; Álvaro Jesús Aguado Marín; Manuel Posada de la Paz
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

9.  Profile of dermatological consultations in Brazil (2018).

Authors:  Hélio Amante Miot; Gerson de Oliveira Penna; Andréa Machado Coelho Ramos; Maria Lúcia Fernandes Penna; Sílvia Maria Schmidt; Flávio Barbosa Luz; Maria Auxiliadora Jeunon Sousa; Sérgio Luiz Lira Palma; José Antonio Sanches Junior
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

Review 10.  Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician.

Authors:  Jessica J Padniewski; Rob L Shaver; Brittney Schultz; David R Pearson
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.